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EAEThe therapeutic potential of natural anti-T-cell receptor (TCR) antibodies is largely unknown.We investigated
whether passive administration of C1-19, a novel natural anti-TCRVβ8 monoclonal antibody, could interfere
with the development of EAE. Treatment with C1-19 prevented myelin basic protein (MBP)-induced EAE in
Vβ8-sufﬁcient B10.PL but not in Vβ8-deﬁcient SJL mice. Furthermore, C1-19 reduced disease severity when
administrated shortly after disease onset. These protective effects of C1-19 correlated with a Th2 bias of the
cytokine response, in the absence of T-cell deletion or anergy. Together, these ﬁndings indicate that natural
anti-TCR antibodies could function as therapeutic tools in autoimmune inﬂammatory diseases.+34 913941641.
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Natural antibodies refer to any type of immunoglobulin present in
the serum of an individual in the absence of deliberate immunization
or infection. These antibodies can be of the IgM, IgG or IgA isotypes
(Lacroix-Desmazes et al., 1998), and recognize several self and foreign
antigens in mice (Baccala et al., 1989; Guilbert et al., 1982; Haury
et al., 1994). Natural auto-antibodies also occur in healthy humans, as
well as in patients with autoimmune disease, where they react with
a wide range of evolutionary conserved cell surface, intracellular and
circulating antigens including DNA, thyroglobulin, senescent cell
antigens, and constant and variable regions of immunoglobulin and
the T cell antigen receptor (TCR) (Lacroix-Desmazes et al., 1998).
However, the precise role of natural antibodies in physiological and
pathological immunity remains unclear.
Experimental autoimmune encephalomyelitis (EAE) is a neuroin-
ﬂammatory disease in which anti-myelin CD4+ T helper (Th) cells have
a key contribution by recruiting and stimulating peripheral macro-
phages and resident microglia, which are the ultimate responsible for
demyelination, oligodendrocyte death and axonal dysfunction (Merrill
et al., 1992). EAE is a surrogate model of humanmultiple sclerosis (MS)that has contributed to understand the mechanisms underlying the
disease and its potential treatment (Steinman and Zamvil, 2005). In
EAEaswell as inMS, the anti-myelinCD4+Tcells responsible for disease
development express an oligoclonal Vβ TCR repertoire (Acha-Orbea
et al., 1988; Kotzin et al., 1991; Oksenberg et al., 1993; Padula et al.,
1991; Urban et al., 1988; Zaller et al., 1990). During EAE, animals
develop both T-cell (Kumar and Sercarz, 1993) and humoral (Hashim
et al., 1990; Hashim et al., 1991) immune responses against the TCR of
encephalitogenic T cells; and these T cells and antibodies protected from
EAE when passively transferred into naïve mice. The mechanisms of
action of regulatory anti-TCR T cells have been analyzed extensively and
may involve anergy (Kumar et al., 1995), deletion (Madakamutil et al.,
2003) or immune deviation of the cytokine response (Kumar and
Sercarz, 1998) of encephalitogenic T cells. In contrast, although the role
of induced anti-TCRantibodies in regulating encephalitogenic T cells has
been addressed in some studies (Aroeira, 2006; Hashim et al., 1990;
Zhou and Whitaker, 1993), the precise mechanisms underlying their
regulatory properties remain to be clearly deﬁned.
Natural anti-TCR antibodies are present in the serumof healthymice
and humans (Marchalonis et al., 1994), and at higher levels in patients
with rheumatoid arthritis, systemic lupus erythematosus (Marchalonis
et al., 1992) and myasthenia gravis (Jambou et al., 2003). Some natural
anti-TCRmonoclonal antibodies have been generated and characterized
(Marchalonis et al., 1994;Robey et al., 2000).However, their therapeutic
potential remains to be determined. In the present study, we tested the
capability of a novel natural anti-TCRVβ8 monoclonal antibody to
protect against autoimmune encephalomyelitis, and characterized its
effects on the T-cell response during disease development.
Fig. 1. C1-19 recognizes surface TCRVβ8 inmouse primary T cells. Spleen cells fromB6μmt
mice were analyzed by three-color ﬂow cytometry after staining with FITC-conjugated
anti-TCRCβ (H57-597) and C1-19 developed with PE-conjugated anti-mouse IgM,
followed by biotinylated anti-TCRVβ8 (MR5-2) and streptavidin-PE-Cy5 staining. TCRCβ
and C1-19 staining of total spleen cells (A). TCRCβ+ cells gated as indicated in A were
analyzed for MR5-2 staining of C1-19− (gate 2; dotted line) and C1-19+ (gate 3; shaded
solid line) cells (B). MR5-2 and C1-19 staining of TCRCβ+ cells (gate 1; as indicated in
A) (C).
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2.1. Mice
Six- to eight-week-old female B10.PL and SJL mice were used in
the experiments. Encephalitogenic T cells in B10.PL mice use mainly
Vβ8.2 (Acha-Orbea et al., 1988) while SJL mice, which were used as
control, have their Vβ8 genes deleted (Behlke et al., 1986) and their
encephalitogenic T cells bear Vβ17a and Vβ4 (Padula et al., 1991).
B10.PL and SJL mice were obtained from Instituto de Ciências
Biomédicas of Universidade de São Paulo, Brasil, and CEMIB
(Campinas, São Paulo), respectively. The study was approved by the
institutional ethical board for animal studies.
2.2. EAE induction
For EAE induction, 200 μg of guinea pig myelin basic protein (MBP;
Sigma-Aldrich, St. Louis, MO) in 100 μl of PBS was emulsiﬁed in an
equal volume of complete Freund's adjuvant (CFA; Life Technologies,
Paisley, UK) supplemented with 400 μg BCG (Instituto Butantã, São
Paulo; SP), and injected subcutaneously into the base of the tail on day
0. Mice also received 200 ng of pertussis toxin (Life Technologies)
intravenously on days 0 and 2. Clinical symptoms were monitored
daily after immunization. The clinical score was graded as follows:
0, no disease; 1, tail limpness; 2, hind limb weakness; 3, hind limb
paralysis; 4, fore limb weakness; and 5, quadriplegia or death.
2.3. C1-19 preparation and treatment
C1-19 is a monoclonal IgM/k antibody obtained by fusion of spleen
cells from a normal non-immunized BALB/c mouse with the non-
secreting P3X63Ag8.653myeloma line. C1-19 was selected based on its
ability to recognize recombinant Vβ8.2 in ELISA and stain the TCRVβ8-
expressing Yac-1 cell line in ﬂow cytometric assays. For further analysis
of antibody speciﬁcity, primary spleen cells from a B cell-deﬁcient
(B6μmt) mouse (Kitamura et al., 1991) were used to avoid nonspeciﬁc
stainingbyendogenousantibodies. TheC1-19-secretinghybridomawas
cultured in RPMI 1640 (Life Technologies) containing 7% B6μmt mouse
serum. IgMconcentration in the culture supernatantwasdeterminedby
standard ELISA. For antibody treatment, culture supernatant containing
10 μg of C1-19 or control irrelevant IgM immunoglobulin (Southern
Biotechnology, Birmingham, AL, USA) diluted in RPMI plus 7% B6μmt
mouse serum were injected i.p. every other day, starting at day 4 after
MBP immunization, or when ﬁrst signs of disease were detected (mice
showing clinical score 1).
2.4. Proliferation assay
Spleen cells (5×106) were cultured for 72 h at 100 μl/well with
50 μg/ml of MBP in RPMI 1640 supplemented with 5% FCS, 50 μM
2-ME, 100 μg streptomycin and 100 U/ml of penicillin, all from Life
Technologies. Cultures were pulsed with 0.5 μCi [3H]-thymidine/
well (Amersham Biosciences, Buckinghamshire, UK) for the last 8 h.
Incorporation of [3H]-thymidine was measured as counts per minute
(cpm) using a liquid scintillation β-counter.
2.5. FACS staining and analysis
For two-color surface staining, 1×106 cells in 30 μl PBSwith0.5%BSA
(Life Technologies) were incubated with each monoclonal antibody on
ice for 20 min. Staining was performed with saturating concentrations
of the followingﬂuorescein isothiocyanate (FITC) andbiotin-conjugated
monoclonal antibodies (BD Biosciences, San Diego, CA, USA): anti-CD3,
anti-CD4, anti-CD8, anti-CD45RB, anti-CD69, anti-TCRVβ3, anti-TCRVβ8
and anti-TCRVβ9. Phycoerythrin-conjugated streptavidin (BD Bios-
ciences) was used to detect biotinylated antibodies. For intracellularcytokine staining, cells were cultured in the presence of Golgi transport
inhibitor for the ﬁnal 4 h of culture. Cells were then surface-stained
with anti-CD4-PerCP, followed by ﬁxation and permeabilization using
Cytoﬁx/Cytoperm (BD Biosciences) according to the manufacturer's
protocol. Finally, cells were stained with anti-IFN-γ-FITC and anti-IL-4-
PE and analyzed by ﬂow cytometry.2.6. Cytokine assays
IFN-γ and IL-4 in culture supernatants were measured by ELISA
using puriﬁed and biotinylated antibody pairs, standards and strepta-
vidin-HRP according to the manufacturer (BD Biosciences); and
o-phenylene-diamine (Sigma-Aldrich) as substrate. Concentrations
Table 1
C1-19 treatment induces activation but not deletion of TCRVβ8+ T cells.
% of CD3+ cells
Treatment TCRVβ8+ TCRVβ8+/CD69+ TCRVβ8+/CD45RBlow
None 26.6±4.1a 19.7±3.5 19.7±2.0
Control IgM 27.0±3.3 21.8±2.1 19.8±2.1
C1-19 25.4±1.8 30.4±1.4 28.6±5.3
B10.PL mice were treated with C119 or control IgM every other day during a week, as
described in Materials and methods. Two hours after the last injection, splenocytes
were collected, double or triple stained for the indicated surface molecules, and
analyzed by ﬂow cytometry. Results are shown as the percentage of cells within the
CD3+ population.
a Mean±SD for four mice in each group and representative of three independent
experiments with similar results.
Fig. 2. C1-19 induces weak T-cell activation in vitro. C57BL/6 splenocytes were stimulated
determination of cell size (forward scatter; FSC) (A), CD69 (B) and CD25 (C) surface expres
cytometry. Numbers within histograms represent the percentage of positive cells in themark
cells stimulated with immobilized F23.1 (1 μg) or C1-19 (10 μg) was determined by intracel
percentage of cells in the quadrant.
65E. Fernández-Malavé, L. Stark-Aroeira / Journal of Neuroimmunology 234 (2011) 63–70were calculated on the basis of standard curves using recombinant IFN-
γ and IL-4.
2.7. Statistical analysis
Statistical analysis was performed using the Mann–Whitney non-
parametric test. P values less than 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. C1-19 recognizes TCRVβ8 on mouse primary T cells
C1-19 is a monoclonal IgM antibody generated by hybridoma
technology using spleen cells from a non-immunized BALB/c mouse.with immobilized (1 μg) anti-TCR Vβ8 C1-19 or F23.1 antibodies for 48 h, followed by
sion in C1-19 (dotted line) or F23.1-stimulated (continuous line) CD4+ T cells by ﬂow
ed region (upper value: F23.1; lower (bold) value: C1-19). Cytokine induction in CD4+ T
lular cytokine staining and ﬂow cytometry (D). Numbers within dot plots represent the
* *
* *
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Fig. 3. C1-19 protects B10.PL but not SJL mice from EAE. EAE was induced in B10.PL or
SJL mice by immunization with MBP in CFA. C1-19 treatment was started at day 4 after
immunization or at the onset of disease (mice showing clinical score 1). Mean±SD
clinical scores (n=5) are shown. Data are representative of three independent
experiments. *Pb0.05; **Pb0.001.
Table 2
C1-19 protects B10.PL mice against EAE.
Control C1-19 C1-19 after onset
Maximal score 3a 0 2 (P=0.013)b
Cumulative score 35 0 24.6 (P=0.043)
Incidence 5/5 0/5 5/5
Values are for the experiment in Fig. 3.
a Mean of ﬁve mice per group.
b P values versus control group.
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TCRVβ8 and the TCRVβ8+ Yac-1 cell line in ELISA and ﬂow cytometry
assays, respectively (data not shown). To determine whether C1-19
was also able to recognize TCRVβ8 on the surface of primary T cells,
we performed three-color staining of spleen cells from B6μmt mice
using a combination of anti-TCRCβ (H57-597), anti-TCR Vβ8.1 and
Vβ8.2 (MR5-2) and C1-19 monoclonal antibodies. C1-19 stained a
fraction of splenic TCRCβ+ cells (Fig. 1A) which were also positive for
staining with the anti-TCRVβ8 antibody MR5-2 (Fig. 1B), while
TCRCβ+C1-19− T cells were not stained by MR5-2. Moreover, the
analysis of C1-19 and MR5-2 staining of TCRCβ+ spleen cells showed
that all T cells stained by MR5-2 were also reactive with C1-19
(Fig. 1C), indicating further that C1-19 recognizes TCRVβ8, and that
C1-19 and MR5-2 bind to non-overlapping epitopes on TCRVβ8.
Together, these data demonstrate that C1-19 is an anti-TCRVβ8
antibody capable of detecting this particular TCRVβ element on the
surface of primary mouse T cells.Fig. 4. Prevention of EAE by C1-19 correlates with deviation of the cytokine response but not
cells from untreated or C1-19-treated B10.PL mice were isolated and analyzed for TCRVβ8 e
were 35±1.9 and 24.6±3.9 (n=5; P=0.2) for untreated and C1-19-treated mice, respecti
anti-MBP proliferative responses by [3H]-thymidine incorporation (B) and cytokine respons
two independent experiments. *Pb0.001.3.2. C1-19 induces activation of TCRVβ8+ T cells
Initially, we analyzed the effect of low-dose antibody on the
frequency and phenotype of TCRVβ8+ spleen T cells from B10.PL mice
treated with 10 μg of C1-19, irrelevant IgM or vehicle i.p. every other
day during a week. The frequency of splenic TCRVβ8+ cells within the
CD3+ (i.e. T-cell) population was similar in mice treated with C1-19,
control IgM or vehicle alone (Table 1), indicating that C1-19 did not
cause deletion of TCRVβ8+ T cells. In contrast, TCRVβ8+ T cells
expressing CD69 or low levels of CD45RB (CD45RBlow), indicative of T
cell activation, were more abundant in mice treated with C1-19 than
in control mice treated with irrelevant IgM or vehicle alone (Table 1).
Together, these data indicate that C1-19 acts in vivo as a non-deleting
but activating antibody for TCRVβ8+ T cells.
Next, we examined the capability of C1-19 to induce T-cell acti-
vation in vitro compared with F23.1, a non-natural anti-TCRVβ8
monoclonal (IgG2a) antibody (Staerz et al., 1985). For this, we
stimulated splenocytes with immobilized (plastic-adsorbed) C1-19 or
F23.1 antibodies. C1-19 was less effective than F23.1 for induction of
cell size increase (Fig. 2A) and surface upregulation of the early
activation markers CD69 (Fig. 2B) and CD25 (Fig. 2C). Furthermore,
C1-19 was a poor inducer of IFN-γ even when used at ten-fold the
amount of F23.1 (Fig. 2D), while provoking a slight but consistent
increase in the frequency of activated T cells expressing IL-4. Thus,
compared with the non-natural F23.1 antibody, C1-19 is a weaker
inducer of early T-cell activation.
3.3. C1-19 prevents EAE induction in B10.PL but not SJL mice
We next evaluated the effect of C1-19 on the development of EAE
induced by MBP immunization in B10.PL mice, in which encephali-
togenic T cells are mainly TCRVβ8+ (Acha-Orbea et al., 1988), or SJL
mice that have all the Vβ8 gene family deleted and their encepha-
litogenic T cells use preferentially Vβ17a and Vβ4 (Padula et al., 1991).
Mice were immunized with MBP in CFA (day 0), and subsequently
treated with low-dose C1-19 or vehicle every other day from day 4.
In another group of B10.PL mice, C1-19 treatment was started at the
onset of disease (mice showing clinical score 1). As shown in Fig. 3,
both B10.PL and SJL mice developed EAE in response to MBP immu-
nization. Strikingly, treatment with C1-19 completely prevented
the establishment of EAE in B10.PL, but not in SJL mice. Furthermore,
C1-19 reduced the clinical score of and prevented disease progression
when administered after the ﬁrst signs of disease (Fig. 3; upper
panel). These results demonstrate that continuous low-dose admin-
istration of C1-19 can prevent EAE speciﬁcally in mice in which
disease is mediated by anti-MBP TCRVβ8+ T cells, such as B10.PL.
In addition, C1-19 could partially treat ongoing EAE in B10.PL mice,
signiﬁcantly reducing the worsening of disease when administered
after the appearance of the ﬁrst clinical signs (Table 2).
3.4. C1-19-mediated protection from EAE is independent from deletion
or anergy, but correlates with deviation of the cytokine response of
MBP-reactive T cells
To conﬁrm that the protective effect of C1-19 on EAE establishment
was not dependent on deletion of TCRVβ8+ cells, we determined the
frequencyof these cells in B10.PLmice treated or notwith C1-19. Onday
10 after EAE induction, the frequency of CD4+Vβ8+ and CD8+Vβ8+ T
cells in spleen (Fig. 4A) and lymphnodes (not shown)were only slightly
reduced in mice treated with C1-19 compared with untreated mice.with deletion or anergy of encephalitogenic T cells. Ten days after EAE induction, spleen
xpression within CD4 and CD8 T-cell subsets by ﬂow cytometry (A). Total cell numbers
vely. Spleen cells from B10.PL and SJL mice were stimulated in vitro with MBP to assess
es by ELISA (C). Results are the mean±SD of ﬁve mice per group and representative of
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to cause major deletion of TCRVβ8+ T cells in mice developing EAE.
Next, we tested the effect of C1-19 on the in vitro recall response
to MBP. For this, B10.PL and SJL splenocytes were harvested on day
10 after EAE induction, and re-stimulated in vitro with MBP for
assessment of proliferation and cytokine responses. T cells from C1-
19-treated B10.PL and SJL mice exhibited MBP-induced proliferation
comparable to that of splenocytes from untreated mice (Fig. 4B),
indicating that MBP-reactive T cells in mice treated with C1-19 are
not anergic. In contrast to this, secretion of the signature Th2 cytokine,
IL-4, in response to antigen was signiﬁcantly augmented by C1-19 in
B10.PL but not SJL mice (Fig. 4C, left). Curiously, MBP-induced pro-
duction of IFN-γ, a signature Th1 cytokine, was not affected by C1-19
treatment in either B10.PL or SJL mice (Fig. 4C, right). Collectively,
these results indicate that C1-19-mediated protection is independent
from deletion or anergy of MBP-speciﬁc T cells, but could be a con-
sequence of deviation of the MBP-speciﬁc response towards a Th2-
like cytokine proﬁle.
3.5. Interruption of C1-19 treatment results in attenuated EAE
Since C1-19 did not cause deletion or anergy of MBP-speciﬁc T cells
during EAE, we were prompted to evaluate the effect of interrupting
C1-19 treatment on the course of the disease. Treatment of B10.PL
with C1-19was started on day 4 and discontinued on day 20. Five days
after stopping C1-19 administration, three out of ﬁve mice developed
disease but with reduced clinical scores compared to untreated
animals (Fig. 5), suggesting a residual therapeutic action of C1-19
treatment. Thus, C1-19-mediated protection against EAE seems to be
dependent on immune regulatory mechanisms requiring the contin-
uous presence of the antibody.
4. Discussion
In the present study, we evaluated the therapeutic potential of a
novel natural anti-TCRVβ8 antibody, named C1-19, in the prevention
and treatment of autoimmune neuroinﬂammation. C1-19 is an IgM
antibody and because this isotype is a strong complement activator,
C1-19 could therefore be potentially cytolytic for TCRVβ8+ T cells.
This was not likely the case, as treatment with the antibody did not
affect the relative abundance of TCRVβ8+ T cells in B10.PL mice.
Instead, C1-19 induced the activation of TCRVβ8+ T cells, as judged by
their up-regulated expression of CD69 and reduced expression of
CD45RB. The activating effect of C1-19 was speciﬁc for cells bearing
TCRVβ8, as the frequency of TCRVβ3+ and TCRVβ9+ T cells
expressing an activated surface phenotype was not altered by in
vivo C1-19 treatment (data not shown).** *
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Fig. 5. Interruption of C1-19 treatment results in development of attenuated EAE. EAE
was induced in B10.PL mice by immunization with MBP in CFA. C1-19 treatment was
started on day 4 after immunization and stopped on day 20 (dashed line). Mean±SD
clinical scores (n=5) are shown. Data are representative of two independent
experiments. *Pb0.01; **Pb0.001.C1-19 prevented EAE in B10.PL but not in SJL mice, which indicates
that the regulatory actions of the antibody result from interaction
with T cells bearing the TCR involved in the anti-MBP response, i.e.
TCRVβ8, and not from nonspeciﬁc effects of administrating IgM
immunoglobulin. Apart from preventing EAE induction, C1-19 also
displayed therapeutic potential, reducing the severity of EAE when
provided upon disease onset.
CD4+ Th cells are the main contributors to the pathogenic
mechanisms responsible for the onset and progression of autoimmune
diseases. CD4+ T-cell inﬁltration of the central nervous system is
required for the development of autoimmune encephalomyelitis, with
inﬁltrating macrophages and resident microglia acting as the ultimate
effectors causing demyelination, oligodendrocyte death and loss of
axonal function (Merrill et al., 1992). Activation of macrophages and
microglia depends critically on pro-inﬂammatory Th1 cytokines, such
as IFN-γ, thus explaining the essential role of Th1 cells in the initiation
and establishment of the neurological disease (Jee and Matsumoto,
2001; Kuchroo et al., 1993; Willenborg et al., 1999). Recently, it was
demonstrated that IL-17-secreting T (Th17) cells also play a critical
role in the development of EAE (Langrish et al., 2005). On the contrary,
Th2/Th3 cytokines such as IL-4, IL-10 and TGF-β have a preventive
effect on EAE (Racke et al., 1994). These regulatory cytokines
antagonize pro-inﬂammatory cytokines, in particular IFN-γ, by
reducing their expression or suppressing their effects (Murphy and
Reiner, 2002; O'Shea and Paul). Therefore, the deviation of the anti-
MBP response towards an IL-4-dominated Th2-like cytokine proﬁle
could, at least partly, explain the beneﬁcial effects of C1-19 in the
prevention and/or amelioration of EAE (Tran et al., 2001). Although
the precisemolecularmechanisms underlying the protective effects of
C1-19 in EAE remain to be further determined, our results clearly
indicate that C1-19, in contrast to previously reported non-natural
antibodies against constant or variable regions of TCR components
(Kohm et al., 2005; Lavasani et al., 2007; Zaller et al., 1990) acts
through mechanisms not involving down-modulation of surface TCR,
deletion or unresponsiveness of antigen-speciﬁc T cells. Yet, the
immune regulatory mechanisms and therapeutic effect triggered by
C1-19 seemed to require the continuous presence of the antibody, at
least at the dose and administration protocol tested in the study. This
latter feature could be partly related to the use of a relatively low
dosage of the antibody, compared with previous studies with non-
natural anti-TCR antibodies (Acha-Orbea et al., 1988; Urban et al.,
1988; Zaller et al., 1990). Alternatively, the higher clearance rate for
IgM compared to IgG antibodies could be underlying the need for
continued administration of C1-19.
Interestingly, mice treatedwith C1-19 presented as FCS-containing
culture supernatant developed a strong IgE response against bovine
albumin, ultimately leading to anaphylactic shock (Stark-Aroeira,
unpublished data). Because IgE responses are Th2-dependent
(Romagnani, 2000; Yazdanbakhsh et al., 2001), the latter ﬁnding
further supports that C1-19 speciﬁcally induces immune deviation of
antigen-speciﬁc T cells towards a Th2-like cytokine proﬁle (Falcone
and Bloom, 1997), an effect that could be secondary to sub-optimal
induction of TCR cross-linking and signaling by C1-19 (Leitenberg
and Bottomly, 1999; Nakayama and Yamashita). This latter property of
C1-19 could in turn be associated with the intrinsic low afﬁnity of
natural antibodies and/or a more restricted cellular expression of FcRs
for IgM (Boes, 2000) compared to their counterparts for IgG.
Importantly, due to their intrinsic low afﬁnity, natural antibodies are
unlikely to induce the strong release of pro-inﬂammatory cytokines
which results in what is known as “ﬁrst dose” syndrome (Alegre et al.,
1990; Ferran et al., 1990), an undesirable side-effect restricting the use
of anti-TCR antibodies as therapeutic agents.
In conclusion, our study demonstrates that C1-19, a natural anti-
TCR monoclonal antibody, can protect against autoimmune enceph-
alomyelitis by, at least partly, skewing the global response to self-
antigen in a Th2 direction and independently from T-cell deletion or
69E. Fernández-Malavé, L. Stark-Aroeira / Journal of Neuroimmunology 234 (2011) 63–70anergy. Thus, C1-19 could be a useful tool in mouse models of
pathology for understanding the immune regulatory properties of
natural anti-TCR antibodies (Boes, 2000; Marchalonis et al., 2002).
Furthermore, our study establishes a proof-of-concept for a therapeu-
tic value of natural anti-TCR antibodies and for development of natural
antibody-based therapies (Holmoy and Vartdal, 2007; Vollmers and
Brandlein, 2005; Zhang et al., 2003) applicable in human autoimmune
inﬂammatory diseases (Adelman et al., 2007; Jambou et al., 2003;
Schluter et al., 2003).
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